ES2423929T3 - Composición farmacéutica que contiene suspensión basada en aceite de partículas finas - Google Patents

Composición farmacéutica que contiene suspensión basada en aceite de partículas finas Download PDF

Info

Publication number
ES2423929T3
ES2423929T3 ES08710384T ES08710384T ES2423929T3 ES 2423929 T3 ES2423929 T3 ES 2423929T3 ES 08710384 T ES08710384 T ES 08710384T ES 08710384 T ES08710384 T ES 08710384T ES 2423929 T3 ES2423929 T3 ES 2423929T3
Authority
ES
Spain
Prior art keywords
active component
particle diameter
pharmaceutical composition
microparticles
medicinally active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08710384T
Other languages
English (en)
Spanish (es)
Inventor
Yasunori Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2423929T3 publication Critical patent/ES2423929T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES08710384T 2007-02-16 2008-02-15 Composición farmacéutica que contiene suspensión basada en aceite de partículas finas Active ES2423929T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007035916 2007-02-16
JP2007035916 2007-02-16
PCT/JP2008/000230 WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Publications (1)

Publication Number Publication Date
ES2423929T3 true ES2423929T3 (es) 2013-09-25

Family

ID=39689861

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08710384T Active ES2423929T3 (es) 2007-02-16 2008-02-15 Composición farmacéutica que contiene suspensión basada en aceite de partículas finas

Country Status (9)

Country Link
US (1) US8309138B2 (cg-RX-API-DMAC7.html)
EP (1) EP2123255B1 (cg-RX-API-DMAC7.html)
JP (2) JP4588791B2 (cg-RX-API-DMAC7.html)
KR (1) KR101434706B1 (cg-RX-API-DMAC7.html)
CN (1) CN101610754A (cg-RX-API-DMAC7.html)
AU (1) AU2008215659B2 (cg-RX-API-DMAC7.html)
CA (1) CA2677842C (cg-RX-API-DMAC7.html)
ES (1) ES2423929T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008099615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
EP4527456A3 (en) 2015-02-03 2025-05-21 Amryt Endo, Inc. Treating acromegaly with oral octreotide
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware Furan based compositions and methods of making thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8546591A (en) 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
DE10399017I1 (de) 1995-02-13 2012-05-16 Searle & Co Substituierte isoxazole zur Behandlung von entzuendung
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
JP2000516244A (ja) 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
TR200000235T2 (tr) 1997-05-22 2000-05-22 G.D. Searle &Co. p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller.
CA2320087C (en) 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 5−アミノイソキサゾール誘導体
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
AU769610B2 (en) * 1998-12-23 2004-01-29 Amgen, Inc. Polyol/oil suspensions for the sustained release of proteins
WO2000039116A1 (en) 1998-12-25 2000-07-06 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
WO2000040220A1 (en) 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
SK286371B6 (sk) * 1999-02-23 2008-08-05 Merck & Co., Inc. Farmaceutický prostriedok
KR100449215B1 (ko) 1999-04-23 2004-09-18 다케다 야쿠힌 고교 가부시키가이샤 5-피리딜-1,3-아졸 화합물, 이의 제조 방법 및 이의 용도
DE60016617T2 (de) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
IN192188B (cg-RX-API-DMAC7.html) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE60104206T2 (de) 2000-09-22 2005-09-22 Galephar M/F Halbfeste arzneizubereitung enthaltend isotretinoin
KR20040073493A (ko) 2001-12-20 2004-08-19 파마시아 코포레이션 경구 투여용 제약 현탁액
JP4611641B2 (ja) 2002-03-20 2011-01-12 エラン ファーマ インターナショナル,リミティド Mapキナーゼ阻害剤のナノ粒子組成物
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
ATE374201T1 (de) 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003255843A1 (en) 2002-08-23 2004-03-11 Ionix Pharmaceuticals Limited 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
WO2004022555A1 (en) 2002-09-06 2004-03-18 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
EA011708B1 (ru) 2002-12-18 2009-04-28 Алгоркс Фармасьютикалз, Инк. Применение транс- капсаицина
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
CA2515939A1 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
WO2004073692A1 (ja) 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
JP5096658B2 (ja) 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
AU2005219525B2 (en) 2004-02-27 2011-08-18 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
SI2275098T1 (sl) * 2004-05-04 2012-12-31 Hormos Medical Ltd. Nove oralne formulacije ospemifena
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CN101080404B (zh) * 2004-12-28 2011-06-08 Aska制药株式会社 嘧啶基异噁唑衍生物
JP2007039408A (ja) 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Also Published As

Publication number Publication date
EP2123255A4 (en) 2010-06-02
EP2123255A1 (en) 2009-11-25
CA2677842A1 (en) 2008-08-21
JPWO2008099615A1 (ja) 2010-05-27
AU2008215659A1 (en) 2008-08-21
CN101610754A (zh) 2009-12-23
US20100092565A1 (en) 2010-04-15
KR101434706B1 (ko) 2014-08-26
WO2008099615A1 (ja) 2008-08-21
KR20090117894A (ko) 2009-11-13
EP2123255B1 (en) 2013-05-15
US8309138B2 (en) 2012-11-13
AU2008215659B2 (en) 2012-11-01
JP2010120974A (ja) 2010-06-03
JP4588791B2 (ja) 2010-12-01
CA2677842C (en) 2014-09-16

Similar Documents

Publication Publication Date Title
ES2423929T3 (es) Composición farmacéutica que contiene suspensión basada en aceite de partículas finas
CN112770726B (zh) 大麻素的缓释配方
ES2496166T3 (es) Dispersión sólida que contiene revaprazán y proceso para la preparación de la misma
ES2665464T3 (es) Forma de dosificación oral sólida que contiene microcápsulas sin costuras
JP4334869B2 (ja) 溶解性または経口吸収性の改善された組成物
ES2565179T3 (es) Nueva composición farmacéutica
ES2593210T3 (es) Composiciones farmacéuticas mejoradas de pimobendán
US20110159049A1 (en) Pharmaceutical composition
KR20090123860A (ko) 실로스타졸을 함유하는 제어방출 제제 및 이의 제조방법
ES3035030T3 (en) Amlodipine formulations
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
BR112014025907B1 (pt) Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento
US20210346302A1 (en) Pharmaceutical Formulation
KR20230097021A (ko) 약학 조성물
ES2606148T3 (es) Composición de disgregación oral de agentes antihistamínicos
BR112019014712A2 (pt) Tratamento médio que compreende a administração entérica de edaravona
JP2015510935A (ja) 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法
JPWO2006087919A1 (ja) 難水溶性物質含有微細化組成物
CN107921017A (zh) 使用卡多曲组合物进行治疗的方法
ES2437916T3 (es) Composición de raloxifeno
CN105307642A (zh) 包含trpa1拮抗剂的纳米颗粒制剂
BR112019018700A2 (pt) composições farmacêuticas e seus usos
EP2682105A1 (en) Orally-disintegrating formulations of dexketoprofen
TWI597063B (zh) 藥物組成物及其製備方法
JP6696082B2 (ja) Mpges−1阻害剤を含むナノ粒子製剤